Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.

McHugh DJ, Chudow J, DeNunzio M, Slovin SF, Danila DC, Morris MJ, Scher HI, Rathkopf DE.

Clin Genitourin Cancer. 2020 Jan 11. pii: S1558-7673(19)30317-9. doi: 10.1016/j.clgc.2019.10.013. [Epub ahead of print]

PMID:
32057715
2.

Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: Can an Agnostic Become a Believer?

Slovin SF.

J Clin Oncol. 2020 Feb 10;38(5):381-383. doi: 10.1200/JCO.19.02921. Epub 2019 Dec 26. No abstract available.

PMID:
31877088
3.

Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?

Slovin SF.

Eur Urol. 2020 Mar;77(3):309-310. doi: 10.1016/j.eururo.2019.12.002. Epub 2019 Dec 19. No abstract available.

PMID:
31864760
4.

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ.

Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6.

PMID:
30725389
5.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.

6.

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME.

Cancer. 2019 Feb 15;125(4):524-532. doi: 10.1002/cncr.31836. Epub 2018 Nov 14.

7.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
8.

Malignant priapism in metastatic prostate cancer: A late event occurring early.

Barrett-Campbell O, Petkovska I, Slovin SF.

Urol Case Rep. 2018 Mar 31;19:1-3. doi: 10.1016/j.eucr.2018.03.001. eCollection 2018 Jul. No abstract available.

9.

Sipuleucel-T: When and for Whom to Recommend It.

Slovin SF.

Oncology (Williston Park). 2017 Dec 15;31(12):900-1, 910-2.

10.

The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.

Slovin SF.

Biomark Med. 2017 Dec;11(12):1149-1159. doi: 10.2217/bmm-2017-0138. Epub 2017 Nov 30. Review.

PMID:
29186979
11.

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group.

Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14. Review.

PMID:
28302580
12.

Radium-223 and concomitant therapies: prospects and prudence.

Yeku O, Slovin SF.

Transl Androl Urol. 2016 Dec;5(6):968-970. doi: 10.21037/tau.2016.11.04. No abstract available.

13.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

14.

Immunotherapy in metastatic prostate cancer.

Slovin SF.

Indian J Urol. 2016 Oct-Dec;32(4):271-276. Review.

15.

Immune Therapy for Prostate Cancer.

Yeku O, Slovin SF.

Cancer J. 2016 Sep/Oct;22(5):334-341. Review.

16.

Immunotherapy for prostate cancer: is prostate an immune responsive tumor?

Slovin SF.

Curr Opin Urol. 2016 Nov;26(6):529-34. doi: 10.1097/MOU.0000000000000334. Review.

PMID:
27533500
17.

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME.

J Clin Oncol. 2016 Jun 1;34(16):1913-20. doi: 10.1200/JCO.2015.65.3154. Epub 2016 Apr 4.

18.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

19.

Immunotherapy for genitourinary malignancies in the here and now!

Slovin SF.

Urol Oncol. 2016 Apr;34(4):169-70. doi: 10.1016/j.urolonc.2015.11.008. Epub 2015 Dec 17. Review. No abstract available.

PMID:
26705103
20.

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI.

Cancer. 2015 Nov 1;121(21):3853-61. doi: 10.1002/cncr.29578. Epub 2015 Jul 15.

21.

Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.

Slovin SF.

Am Soc Clin Oncol Educ Book. 2015:e275-83. doi: 10.14694/EdBook_AM.2015.35.e275.

22.

Biomarkers for immunotherapy in genitourinary malignancies.

Slovin SF.

Urol Oncol. 2016 Apr;34(4):205-13. doi: 10.1016/j.urolonc.2015.02.007. Epub 2015 Mar 16. Review.

PMID:
25791754
23.

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

Yeku O, Slovin SF.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):843-9. doi: 10.1517/17425255.2015.1021332. Epub 2015 Mar 4. Review.

PMID:
25740232
24.

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, Seyboth BM, Kampel LJ, Danila DC, Rathkopf DE, Slovin SF, Scher HI, Morris MJ.

Clin Genitourin Cancer. 2015 Aug;13(4):e305-e309. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22. No abstract available.

25.

Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.

Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA, Leventhal H, Diefenbach MA.

Med Decis Making. 2015 May;35(4):477-86. doi: 10.1177/0272989X14558424. Epub 2014 Nov 10.

26.

Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.

27.

American Cancer Society prostate cancer survivorship care guidelines.

Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, Salner AL, Zelefsky MJ, Aragon-Ching JB, Slovin SF, Wittmann DA, Hoyt MA, Sinibaldi VJ, Chodak G, Pratt-Chapman ML, Cowens-Alvarado RL.

CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49. doi: 10.3322/caac.21234. Epub 2014 Jun 10. Erratum in: CA Cancer J Clin. 2014 Nov-Dec;64(6):445.

28.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.

29.

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.

Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P.

Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi: 10.1126/scitranslmed.3008002.

30.

Challenges and recommendations for early identification of metastatic disease in prostate cancer.

Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group.

Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8. Review.

PMID:
24411213
31.

Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design.

Slovin SF.

Immunotargets Ther. 2013 Dec 16;3:1-8. doi: 10.2147/ITT.S30821. eCollection 2014. Review.

32.

Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.

Slovin SF.

Immunotherapy. 2013 Dec;5(12):1347-55. doi: 10.2217/imt.13.140. Review.

PMID:
24283845
33.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

34.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM.

Ann Oncol. 2013 Jul;24(7):1813-1821. doi: 10.1093/annonc/mdt107. Epub 2019 Dec 4.

35.

Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?

Snyder A, Tepper JE, Slovin SF.

Semin Oncol. 2013 Jun;40(3):347-60. doi: 10.1053/j.seminoncol.2013.04.009. Review.

PMID:
23806499
36.

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ.

Cancer. 2013 Sep 1;119(17):3186-94. doi: 10.1002/cncr.28103. Epub 2013 Jun 13.

37.

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.

38.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM.

Ann Oncol. 2013 Jul;24(7):1813-21. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27.

39.

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, Israel R, Scher HI, Morris S.

Vaccine. 2013 Jan 30;31(6):943-9. doi: 10.1016/j.vaccine.2012.11.096. Epub 2012 Dec 13.

PMID:
23246260
40.

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.

Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA.

Ann Oncol. 2012 Oct;23(10):2714-9. Epub 2012 May 2.

41.

Are we trumping bone disease in prostate cancer?

Slovin SF.

Oncology (Williston Park). 2011 Dec;25(14):1390, 1393. No abstract available.

42.

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1089-97. doi: 10.1007/s00280-011-1789-3. Epub 2011 Nov 29.

43.

Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.

Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ.

Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. doi: 10.1007/s00280-011-1759-9. Epub 2011 Oct 22.

44.

Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.

Gin DY, Slovin SF.

Curr Drug ther. 2011 Aug;6(3):207-212.

45.

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.

Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Alland L, Wilding G, Scher HI; Prostate Cancer Clinical Trials Consortium.

Clin Cancer Res. 2011 Feb 15;17(4):880-7. doi: 10.1158/1078-0432.CCR-10-2955. Epub 2010 Dec 3.

46.

Seeking informed consent to Phase I cancer clinical trials: identifying oncologists' communication strategies.

Brown R, Bylund CL, Siminoff LA, Slovin SF.

Psychooncology. 2011 Apr;20(4):361-8. doi: 10.1002/pon.1748. Epub 2010 Apr 7.

PMID:
20878842
47.

A clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?

Slovin SF.

Immunotherapy. 2010 Mar;2(2):155-8. doi: 10.2217/imt.10.5.

PMID:
20635924
48.

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.

Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP.

Mod Pathol. 2010 Aug;23(8):1104-12. doi: 10.1038/modpathol.2010.95. Epub 2010 May 21.

49.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.

Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI.

Clin Genitourin Cancer. 2009 Oct;7(3):E77-82. doi: 10.3816/CGC.2009.n.028.

PMID:
19815486
50.

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI.

Eur Urol. 2009 Aug;56(2):237-44. doi: 10.1016/j.eururo.2009.03.073. Epub 2009 Apr 3.

Supplemental Content

Loading ...
Support Center